Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefitfrom anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

    Research output: Contribution to journalLetterpeer-review

    6 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)1635
    Number of pages1
    JournalBritish Journal of Cancer
    Volume113
    Issue number11
    DOIs
    Publication statusPublished - 1 Dec 2015

    Cite this